Arcus Biosciences Stock Total Asset
| RCUS Stock | USD 13.10 0.40 3.15% |
Arcus Biosciences fundamentals help investors to digest information that contributes to Arcus Biosciences' financial success or failures. It also enables traders to predict the movement of Arcus Stock. The fundamental analysis module provides a way to measure Arcus Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcus Biosciences stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 1.3 B | 767.6 M |
Arcus | Total Asset |
Arcus Biosciences Company Total Asset Analysis
Arcus Biosciences' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Arcus Biosciences Total Asset | 1.09 B |
Most of Arcus Biosciences' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcus Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arcus Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcus Biosciences is extremely important. It helps to project a fair market value of Arcus Stock properly, considering its historical fundamentals such as Total Asset. Since Arcus Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcus Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcus Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Arcus Total Asset Historical Pattern
Today, most investors in Arcus Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arcus Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Arcus Biosciences total asset as a starting point in their analysis.
Arcus Biosciences Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Arcus Total Assets
Total Assets |
|
Based on the latest financial disclosure, Arcus Biosciences has a Total Asset of 1.09 B. This is 85.44% lower than that of the Biotechnology sector and 44.58% lower than that of the Health Care industry. The total asset for all United States stocks is 96.28% higher than that of the company.
Arcus Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcus Biosciences' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcus Biosciences could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics of similar companies.Arcus Biosciences is currently under evaluation in total asset category among its peers.
Arcus Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcus Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcus Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Arcus Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Arcus Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arcus Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcus Biosciences' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | Parkman Healthcare Partners Llc | 2024-09-30 | 1 M | Bnp Paribas Investment Partners Sa | 2024-09-30 | 931 K | Decheng Capital Llc | 2024-12-31 | 808.8 K | Braidwell Lp | 2024-12-31 | 802.1 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 714.5 K | Goldman Sachs Group Inc | 2024-09-30 | 703.3 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 673.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 579.6 K | Blackrock Inc | 2024-09-30 | 9.7 M | Vanguard Group Inc | 2024-12-31 | 5.4 M |
Arcus Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.03) % | ||||
| Operating Margin | (2.19) % | ||||
| Current Valuation | 167.8 M | ||||
| Shares Outstanding | 91.51 M | ||||
| Shares Owned By Insiders | 6.41 % | ||||
| Shares Owned By Institutions | 94.86 % | ||||
| Number Of Shares Shorted | 6.38 M | ||||
| Price To Earning | 27.69 X | ||||
| Price To Book | 2.12 X | ||||
| Price To Sales | 4.56 X | ||||
| Revenue | 117 M | ||||
| Gross Profit | (177 M) | ||||
| EBITDA | (283 M) | ||||
| Net Income | (307 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 14.48 X | ||||
| Total Debt | 11 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.22 X | ||||
| Book Value Per Share | 6.17 X | ||||
| Cash Flow From Operations | (306 M) | ||||
| Short Ratio | 10.46 X | ||||
| Earnings Per Share | (3.19) X | ||||
| Target Price | 33.2 | ||||
| Number Of Employees | 577 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 1.2 B | ||||
| Total Asset | 1.09 B | ||||
| Retained Earnings | (849 M) | ||||
| Working Capital | 647 M | ||||
| Net Asset | 1.09 B |
About Arcus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.